QuidelOrtho Corporation(QDEL) Stock Research - Grey Stern Research

QuidelOrtho Corporation (QDEL) Stock Analysis

$25.17 (-0.40%)

QDEL Financial Performance


Use the table below to view QuidelOrtho Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $25.17 -
52 Week Low $24.44 -
52 Week High $49.45 -
Market Cap $1.7 Billion 13/19
Gross Margin 93% 1/19
Profit Margin -22% 14/19
EBITDA margin -14% 16/19
Q3 - 2024 Revenue $707.8 Million 4/19
Q3 - 2024 Earnings -$153.4 Million 18/19
Q3 - 2024 Free Cash Flow $0 Million 18/19
Trailing 4 Quarters Revenue $2.8 Billion 4/19
Trailing 4 Quarters Earnings -$2.0 Billion 19/19
Quarterly Earnings Growth -2291% 19/19
Annual Earnings Growth -6418% 19/19
Quarterly Revenue Growth -5% 19/19
Annual Revenue Growth -7% 19/19
Cash On Hand $98.3 Million 10/19
Short Term Debt $341.8 Million 3/19
Long Term Debt $167.2 Million 10/19

QuidelOrtho Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare QuidelOrtho Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 11/19
PS 0.61 19/19
PB 0.56 19/19
PC 17.27 13/19
Liabilities to Equity 1.14 10/19
ROA -0.31 18/19
ROE -0.67 18/19
Current Ratio 1.88 10/19
Quick Ratio 0.03 18/19
Long Term Debt to Equity 0.06 16/19
Debt to Equity 0.17 13/19
Burn Rate 0.40 12/19
Cash to Cap 0.06 4/19
CCR 18/19
EV to EBITDA -21.00 13/19
EV to Revenue 0.76 19/19

Company Details

QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.

CEO: Mr. Douglas Bryant

Website: https://www.quidelortho.com

Address: 9975 Summers Ridge Road San Diego, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

QuidelOrtho Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to QuidelOrtho Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Glaukos Corporation GKOS $5.1 Billion
Tandem Diabetes Care, Inc. TNDM $1.1 Billion
DexCom, Inc. DXCM $26.9 Billion
LivaNova PLC LIVN $1.9 Billion
Insulet Corporation PODD $17.3 Billion
Masimo Corporation MASI $8.2 Billion
Bruker Corporation BRKR $5.5 Billion
NuVasive, Inc. NUVA $2.1 Billion
STERIS plc STE $21.8 Billion
Penumbra, Inc. PEN $10.7 Billion
CONMED Corporation CNMD $1.5 Billion
OrthoPediatrics Corp. KIDS $521.5 Million
Inspire Medical Systems, Inc. INSP $4.5 Billion
ShockWave Medical, Inc. SWAV $12.6 Billion
SI-BONE, Inc. SIBN $588.0 Million
Inari Medical, Inc. NARI $4.7 Billion
Pulmonx Corporation LUNG $181.9 Million
NeuroPace, Inc. NPCE $351.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
QDEL Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 707.8 Million -$153.4 Million
Q3 2024 $ 727.1 Million -$19.9 Million
Q2 2024 $ 636.3 Million -$147.7 Million
Q1 2024 $ 709.7 Million -$1.7 Billion
Q4 2023 $ 742.6 Million $7.0 Million
Q3 2023 $ 744.0 Million -$12.7 Million
Q2 2023 $ 665.1 Million -$53.2 Million
Q1 2023 $ 846.1 Million $48.8 Million

View All

QDEL Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $98.3 Million $6.4 Billion $509.0 Million $3.0 Billion
Q3 2024 $143.7 Million $6.8 Billion $2.7 Billion $3.2 Billion
Q2 2024 $107.0 Million $6.7 Billion $2.8 Billion $3.2 Billion
Q1 2024 $78.5 Million $6.7 Billion $2.6 Billion $3.3 Billion
Q4 2023 $118.9 Million $8.6 Billion $2.4 Billion $5.0 Billion
Q3 2023 $149.3 Million $8.5 Billion $2.6 Billion $5.0 Billion
Q2 2023 $178.6 Million $8.6 Billion $2.5 Billion $5.0 Billion
Q1 2023 $353.9 Million $8.8 Billion $2.8 Billion $5.0 Billion

View All

QDEL Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $235.4 Million $117.5 Million $37.0 Million
Q2 2024 -$133.2 Million -$35.3 Million $28.5 Million
Q1 2024 -$66.8 Million -$66.1 Million -$40.4 Million
Q4 2023 $106.2 Million $0 $106.2 Million
Q3 2023 $41.5 Million $0 -$29.7 Million
Q2 2023 $50.1 Million $0 $50.1 Million
Q1 2023 $208.7 Million $19.8 Million $61.0 Million
Q4 2022 $107.7 Million -$61.7 Million $80.7 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions